首页|谷氨酰胺联合生长抑素、埃索美拉唑对重症胰腺炎患者疗效及血清炎性因子影响

谷氨酰胺联合生长抑素、埃索美拉唑对重症胰腺炎患者疗效及血清炎性因子影响

扫码查看
目的 观察谷氨酰胺与生长抑素和埃索美拉唑联用对重症胰腺炎的治疗效果和血清炎性因子水平的影响。方法 选择厦门医学院附属第二医院2021年1月至2023年1月住院治疗的120例重症胰腺炎患者,按随机数表法分为观察组60例、对照组60例。对照组口服埃索美拉唑,观察组加用生长抑素和谷氨酰胺,对其临床疗效进行比较。结果 观察组临床总有效率高于对照组,差异有统计学意义(P<0。05)。观察组血清炎性指标优于对照组,差异有统计学意义(P<0。05)。观察组肠黏膜屏障指标优于对照组,差异有统计学意义(P<0。05)。结论 应用谷氨酰胺、生长抑素和埃索美拉唑等药物治疗重症胰腺炎效果明显,可明显改善重症胰腺炎患者的炎性反应,增强肠黏膜屏障功能。
Efficacy of glutamine combined with somatostatin and esomeprazole on patients with severe pancreatitis and its effect on serum inflammatory factors
Objective The of this study is to discuss the efficacy of the glutamine combined growth inhibitor,Esso Beauty,in the treatment of acute pancreatitis and its impact on the level of serum inflammatory cytokines.Methods A total of 120 patients with acute pancreatitis admitted to the Second Affiliated Hospital of Xiamen Medical College from January 2021 to January 2023 were randomly divided into a control group(n=60)and a treatment group(n=60).The control group was treated with esomeprazole,while the treatment group was treated with growth inhibitors and glutamine.The clinical efficacy of the two groups was compared.Results The total clinical effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).The serum indicators of the observation group were better than those of the control group,and the difference was statistically significant(P<0.05).The intestinal mucosal barrier index in the observation group was better than that in the control group,and the difference was statistically significant(P<0.05).Conclusion The administration of glutamine,growth inhibitors and esomeprazole has been demonstrated to significantly improve inflammatory response and intestinal mucosal barrier function in patients with acute pancreatitis.

GlutamineEsomeprazoleSomatostatinSevere pancreatitisClinical efficacySerum inflammatory factors

何飞、李建江、高清、王兴梅

展开 >

厦门医学院附属第二医院重症医学科,福建厦门 361021

谷氨酰胺 埃索美拉唑 生长抑素 重症胰腺炎 临床疗效 血清炎性因子

厦门医学院附属第二医院横向科研项目

2021230

2024

中国医药科学
海峡两岸医药卫生交流协会 二十一世纪联合创新(北京)医药科学研究院

中国医药科学

影响因子:1.083
ISSN:2095-0616
年,卷(期):2024.14(13)